ACE-2-derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2

SARS-CoV-2, a novel coronavirus causing overwhelming death and infection worldwide, has emerged as a pandemic Compared to its predecessor SARS-CoV, SARS-CoV-2 is more infective for being highly contagious and exhibiting tighter binding with host angiotensin-converting enzyme 2 (hACE-2) The entry of the virus into host cells is mediated by the interaction of its spike protein with hACE-2 Thus, a peptide that has a resemblance to hACE-2 but can overpower the spike protein-hACE-2 interaction will be a potential therapeutic to contain this virus The non-interacting residues in the receptor-binding domain of hACE-2 have been mutated to generate a library of 136 new peptides Out of this library, docking and virtual screening discover seven peptides that can exert a stronger interaction with the spike protein than hACE-2 A peptide derived from simultaneous mutation of all the non-interacting residues of hACE-2 yields two-fold stronger interaction than hACE-2 and thus turns out here to be the best peptide-inhibitor of the novel coronavirus The binding of the spike protein and the best peptide-inhibitor with hACE-2 is explored further by molecular dynamics, free energy, and principal component analysis to demonstrate its efficacy Further, the inhibition assay study with the best peptide inhibitor is in progress